Paragon Biosciences
Paragon Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological conditions, sleep-wake disorders, and other diseases with high unmet medical needs, utilizing generative AI in their research.
Services
Paragon Biosciences focuses on developing innovative treatment options for patients suffering from sleep-wake disorders, such as narcolepsy, and other neurological conditions. The company specializes in using generative AI to design novel protein systems, aiming to address diseases with high unmet medical needs. Their portfolio includes late-stage developments in treatments for central nervous system disorders, skin and connective tissue diseases, and life-changing regenerative medicines.
Products
Paragon Biosciences has successfully developed and commercialized the first nonscheduled treatment for narcolepsy. Their late-stage developments include a new class of drugs for patients with Tourette syndrome, cell and gene therapy treatments for skin and connective tissue diseases, and regenerative medicines aimed at restoring vision lost to degenerative retinal diseases.
Research and Development
The company is committed to advancing therapeutic discovery and drug development through the use of generative AI. This technology helps design novel protein systems, which are crucial for developing treatments for challenging diseases. Paragon Biosciences is in late-stage development for several promising therapies, including drugs for Tourette syndrome and Cell and Gene Therapy for skin and connective tissue diseases.
Recent Achievements
In 2023, Paragon Biosciences was ranked among the Top 25 Fastest-Growing Companies in North America according to the Deloitte Technology Fast 500. Additionally, the company announced an $81 million financing round aimed at advancing their work in generative AI for therapeutic discovery and drug development.